Interplay Between Thiamine and p53/p21 Axes Affects Antiproliferative Action of Cisplatin in Lung Adenocarcinoma Cells by Changing Metabolism of 2-Oxoglutarate/Glutamate.
A549 adenocarcinoma cells
TCA cycle
cisplatin
glutamate metabolism
p21
p53
thiamine deficiency
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
01
2021
accepted:
05
03
2021
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
Thiamine (vitamin B1) is often deficient in oncopatients, particularly those undergoing chemotherapy. However, interaction between the thiamine deficiency and anticancer action of drugs has not been characterized. A major natural thiamine derivative, thiamine diphosphate (ThDP), is a coenzyme of central metabolism, also known to affect transcriptional activity of the master metabolic regulator and genome guardian p53. A direct transcriptional target of p53, p21, regulates cell cycle dynamics and DNA damage response. Our work focuses on dependence of the action of the DNA damaging anticancer drug cisplatin on metabolic regulation through p53/p21 axes and cellular thiamine status in human lung adenocarcinoma cells A549. These cells are used as a model of a hardly curable cancer, known to develop chemoresistance to platinum drugs, such as cisplatin. Compared to wild type (A549
Identifiants
pubmed: 33868388
doi: 10.3389/fgene.2021.658446
pmc: PMC8047112
doi:
Types de publication
Journal Article
Langues
eng
Pagination
658446Informations de copyright
Copyright © 2021 Aleshin, Zhou, Krishnan, Karlsson and Bunik.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Neurobiol. 2017 Sep;54(7):5440-5448
pubmed: 27596507
Cell Rep. 2016 Oct 4;17(2):366-373
pubmed: 27705786
PLoS One. 2016 Jun 16;11(6):e0157113
pubmed: 27310615
Protein Cell. 2018 Feb;9(2):216-237
pubmed: 28748451
Int J Mol Sci. 2020 May 26;21(11):
pubmed: 32466567
Psychosomatics. 2016 Jan-Feb;57(1):71-81
pubmed: 26791514
Oncotarget. 2017 Jul 25;8(30):49275-49292
pubmed: 28525376
Head Neck. 2016 Apr;38 Suppl 1:E934-40
pubmed: 25994759
Pharm Res. 2016 Jul;33(7):1769-81
pubmed: 27091032
Palliat Support Care. 2020 Oct;18(5):609-613
pubmed: 33040773
Biochemistry (Mosc). 2019 Aug;84(8):829-850
pubmed: 31522667
Cancers (Basel). 2019 Aug 14;11(8):
pubmed: 31416295
Oncol Rep. 2020 Dec 01;:
pubmed: 33416171
Drug Chem Toxicol. 2014 Jul;37(3):290-4
pubmed: 24215635
Am J Cancer Res. 2016 Nov 01;6(11):2690-2699
pubmed: 27904781
Nature. 2013 Jan 31;493(7434):689-93
pubmed: 23334421
J Biol Chem. 2001 Jan 12;276(2):1114-8
pubmed: 11038362
Oncotarget. 2015 Mar 20;6(8):5978-89
pubmed: 25788274
Cutan Ocul Toxicol. 2016 Sep;35(3):222-7
pubmed: 26339826
Neurotox Res. 2019 Nov;36(4):777-787
pubmed: 30972556
Clin Cancer Res. 2014 Apr 1;20(7):1990-2000
pubmed: 24516043
Front Pharmacol. 2020 Dec 03;11:598880
pubmed: 33424607
Biomed Res Int. 2013;2013:783809
pubmed: 23841092
Indian J Pharmacol. 2013 Jul-Aug;45(4):339-43
pubmed: 24014907
Oncotarget. 2015 Nov 24;6(37):40036-52
pubmed: 26503465
Free Radic Biol Med. 2006 Jan 1;40(1):110-9
pubmed: 16337884
Med Sci Monit. 2019 Apr 02;25:2386-2396
pubmed: 30938333
Mol Aspects Med. 2013 Apr-Jun;34(2-3):373-85
pubmed: 23506878
Mol Reprod Dev. 2015 Jul-Aug;82(7-8):518-29
pubmed: 26153368
Eur J Clin Nutr. 2021 Mar;75(3):564-566
pubmed: 32895510
Drug Metab Pharmacokinet. 2015 Aug;30(4):276-81
pubmed: 26190800
Palliat Support Care. 2018 Aug 3;:1-3
pubmed: 30073944
J Diabetes Investig. 2011 Apr 7;2(2):123-31
pubmed: 24843471
Oncotarget. 2016 May 3;7(18):26400-21
pubmed: 27027236
Chem Sci. 2019 Jan 22;10(10):3089-3095
pubmed: 30996891
Cell Rep. 2016 Oct 11;17(3):876-890
pubmed: 27732861
Psychooncology. 2017 Sep;26(9):1384-1389
pubmed: 27228202
J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):221-9
pubmed: 25316705
Anticancer Agents Med Chem. 2019;19(14):1775-1783
pubmed: 30914033
Naunyn Schmiedebergs Arch Pharmacol. 2008 Sep;378(3):283-91
pubmed: 18509620
BMC Cancer. 2011 Sep 21;11:399
pubmed: 21933447
Free Radic Biol Med. 2019 May 1;135:167-181
pubmed: 30880247
Oncol Lett. 2018 Jul;16(1):801-808
pubmed: 29971135
Cancer Sci. 2019 Nov;110(11):3453-3463
pubmed: 31444923
Biochem Biophys Res Commun. 2019 Apr 16;511(4):719-724
pubmed: 30827507
Oncotarget. 2018 Oct 23;9(83):35422-35438
pubmed: 30459934
PLoS One. 2017 Jul 26;12(7):e0181081
pubmed: 28746345
Int J Mol Sci. 2020 Oct 15;21(20):
pubmed: 33076245
Cancer Lett. 2016 Oct 10;381(1):96-103
pubmed: 27477897
J Biol Chem. 2014 Feb 14;289(7):4405-16
pubmed: 24379411
Sci Adv. 2020 Oct 9;6(41):
pubmed: 33036978
Hum Exp Toxicol. 2014 Jan;33(1):14-21
pubmed: 23632005
Biopharm Drug Dispos. 2014 Nov;35(8):431-49
pubmed: 24532461
Mol Cell Biol. 2004 Nov;24(22):9958-67
pubmed: 15509798
Sci Rep. 2015 Jul 27;5:12583
pubmed: 26212886
Int J Mol Sci. 2020 Dec 31;22(1):
pubmed: 33396303
Oncol Res. 2016;23(3):119-28
pubmed: 26931434
OMICS. 2020 Nov;24(11):667-678
pubmed: 32991258
Nan Fang Yi Ke Da Xue Xue Bao. 2013 Sep;33(9):1253-9
pubmed: 24067199
J Neurochem. 2020 Apr;153(1):80-102
pubmed: 31886885
J Biochem Mol Toxicol. 2013 Aug;27(8):398-405
pubmed: 23716490
Mol Med Rep. 2019 Apr;19(4):2921-2926
pubmed: 30720086
Oncotarget. 2015 Apr 20;6(11):9271-83
pubmed: 25797253
Biochemistry (Mosc). 2020 Jul;85(7):801-807
pubmed: 33040724
Neurooncol Pract. 2016 Sep;3(3):196-207
pubmed: 31386087
Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):406-17
pubmed: 24968580
Neuroscience. 2007 Feb 9;144(3):1045-56
pubmed: 17137721
Jpn J Clin Oncol. 2018 Apr 1;48(4):303-307
pubmed: 29474642
BMC Cancer. 2018 May 11;18(1):559
pubmed: 29751795